{"classes":[{"categories":[{"measurements":[{"comment":"The median overall survival was not reached as more than 50% of patients were still live at the time of the data cut-off using the Kaplan-Meier method.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The median overall survival was not reached as more than 50% of patients were still live at the time of the data cut-off using the Kaplan-Meier method.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"Overall survival was assessed by the time to death or censoring. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of data cut. The survival time was analyzed using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants began treatment with ruxolitinib 15 or 20 mg taken orally twice a day based on Baseline platelet count. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily.","id":"OG000","title":"Ruxolitinib"},{"description":"Placebo tablets matching ruxolitinib were administered orally twice a day at a starting dose based on Baseline platelet count. Doses were titrated using the same guidelines as for active drug. Patients meeting pre-specified requirements were given the opportunity to cross over to ruxolitinib treatment.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"ITT population","reportingStatus":"POSTED","timeFrame":"From randomization to the data cut-off date (up to 14 months).","title":"Overall Survival Time","type":"SECONDARY","unitOfMeasure":"weeks"}